The Effects of Transcutaneous Acupoint Electrical Stimulation on Cancer-related Fatigue and Negative Emotions in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yubo He, Minchi Yuan, Chun He, Danwei Zhu, and Feida Wang

1Department of Rehabilitation Medicine, The First People’s Hospital of Jiashan/Jiashan Branch of the Second Affiliated Hospital of Zhejiang University School of Medicine, Jiaxing, China
2Department of Oncology, The First People’s Hospital of Jiashan/Jiashan Branch of the Second Affiliated Hospital of Zhejiang University School of Medicine, Jiaxing, China
3Department of General Medicine, The First People’s Hospital of Jiashan/Jiashan Branch of the Second Affiliated Hospital of Zhejiang University School of Medicine, Jiaxing, China
4Department of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China

Correspondence should be addressed to Feida Wang; wang_fdoctor@medicine-edu.cn

Received 19 May 2022; Revised 6 July 2022; Accepted 12 July 2022; Published 31 July 2022

Academic Editor: Mohammad Farukh Hashmi

Copyright © 2022 Yubo He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transcutaneous electrical acupoint stimulation (TEAS) is a noninvasive and therapeutic technique that stimulated the acupoint by delivering electricity. Whether TEAS could relieve cancer-related fatigue (CRF), anxiety, and depression and improve the quality of life in cancer patients remains controversial. Thus, we conducted a thorough literature search of electronic Chinese and English databases for randomized controlled trials (RCTs) reporting the effect of CRF, anxiety, depression, and quality of life in cancer patients from inception to July 1st, 2021. The Cochrane Collaboration Risk of Bias criteria were used to assess the risk of bias for each included RCT. Continuous variables were analyzed using standardized mean difference (SMD) and 95% confidence interval (CI). A fixed-effects model was used for the meta-analysis of all outcomes. A total of nine RCTs with 924 cancer patients were included in this analysis, including 460 patients in the intervention group and 464 patients in the control group. We found that TEAS could significantly reduce CRF, depression, and anxiety (SWD = −0.83, 95% CI: −0.99 to −0.66, P < 0.05) and improve the quality of life (SWD = −1.37, 95% CI: −2.34 to −0.40, P < 0.05). The funnel plot analysis revealed no significant publication bias. We conclude that TEAS is beneficial for reducing CRF, depression, and anxiety and improving the quality of life of cancer patients, but additional high-quality evidence in the future is entailed to support this.

1. Introduction

Tumor cells can be eliminated through a variety of methods, including surgery, chemotherapy, radiotherapy, molecular targeted therapy, and immunotherapy [1]. However, most of these treatments are associated with significant side effects. For instance, 30–60% of cancer patients undergoing treatment reportedly develop severe cancer-related fatigue (CRF), which can lead to treatment interruption because of poor results from reduced physical function and reduced motor capacity [1]. Fatigue usually decreases within a year after treatment completion, but CRF is expected to last for months or even years in a small subset of patients after successful treatment [2]. In addition, cancer patients may
develop serious negative emotions such as depression and anxiety, which further adversely affect the overall quality of life.

Transcutaneous electrical acupoint stimulation (TEAS) is a noninvasive therapeutic approach based on percutaneous electrical nerve stimulation [3]. TEAS uses a combination of electrodes with traditional Chinese acupuncture to stimulate specific acupoints of the body without needles, relieving symptoms and facilitating recovery [3]. Currently, the clinical application of TEAS in cancer patients and those with negative emotions remains controversial. Hou et al. [3] reported that the Revised Piper Fatigue Scale (RPFS) scores of the interventional group decreased significantly compared with the control group after 28 days of TEAS treatment for lung cancer, indicating that TEAS may help reduce the CRF in lung cancer patients. However, there was no statistical difference in the RPFS scores between the interventional and control groups in terms of the effect of TEAS on CRF in breast cancer patients [4]. The therapeutic effects of TEAS on CRF, negative emotions, and quality of life of cancer patients remain largely unknown. Therefore, our review aims to systemically analyze and study on the effect of TEAS in cancer patients and to quantify the effects of TEAS.

2. Methods

2.1. Search Strategy. Investigators searched for eligible literature from the following electronic databases: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), Wanfang Database, and Chinese Science and Technology Journal Database (VIP). For example, we searched PubMed using combinations of medical subject headings terms: (tumor [Title/Abstract]) OR (cancer [Title/Abstract]) AND (transcutaneous electrical acupoint stimulation [Title/Abstract]) AND (fatigue [Title/Abstract]) OR (depression [Title/Abstract]) OR (anxiety [Title/Abstract]). Manual hand-searching of reference lists and relevant papers was performed to identify additional studies or dissertations of relevance.

2.2. Inclusion and Exclusion Criteria. The inclusion criteria were as follows: (I) Studies involving adult (age >18 years) hospitalized patients with a cancer diagnosis based upon imaging or pathology [5]; (II) patients included were lucid without mental disorders; (III) studies involving the following intervention measures: the intervention group adopted TEAS whereas the control group adopted conventional nursing care or health education nursing method; (IV) primary study outcome was changes of CRF, and secondary outcomes were changes of negative emotions (depression or anxiety) and quality of life; and (V) study design was randomized controlled trials (RCTs). The exclusion criteria were as follows: (I) reviews or duplicate studies; (II) studies where the specific data could not be extracted; and (III) studies involving TEAS combined with other interventions in the intervention group.

2.3. Data Extraction. Two reviewers screened the search results by checking the titles and abstracts according to the inclusion criteria and subsequently read the full texts of the articles to select relevant studies. Data were independently extracted by two reviewers using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions [6]. The form includes four domains: (I) a description of the characteristics of the included studies (year of publication, name of the first author, study design); (II) characteristics of the participants (sample size, demographics, and disease information); (III) intervention (type and duration); and (IV) report results and relevant questionnaires. Disagreements between the two reviewers were resolved through discussion or consultation with a third member of the review team.

2.4. Quality Assessment. The Cochrane Collaboration Risk of Bias criteria were used to assess the risk of bias for each included study [7]. The following seven domains were considered: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other sources of bias. Studies that fully met these criteria were classified as “A” (high-quality), whereas those that met some of the above criteria were classified as “B” (medium quality). Studies that did not meet any of the above criteria were classified as “C” (low quality) and excluded from the analysis.

2.5. Statistical Analyses. The meta-analysis was conducted using RevMan software (Version 5.3; Cochrane Collaboration, Oxford, England). The mean difference (MD) or standardized mean difference (SMD) with a 95% confidence interval (CI) was used to calculate the effect size for continuous variables. The magnitude of interstudy heterogeneity was quantified using the Cochran Q test (test level is $\alpha = 0.1$) and the $I^2$ statistics. When $P < 0.05$ and $I^2 > 50\%$, the random-effects model was used to measure heterogeneity; otherwise, the fixed-effects model was used, and subgroup analysis was conducted to detect the potential source of heterogeneity. Finally, the publication bias was qualitatively analyzed by the funnel plots and quantitatively by Egger’s test.

3. Results

3.1. Overall Summary of Meta-Analyses. A total of 267 studies were initially identified. We excluded 120 duplicate articles, 23 case reports or reviews, 32 articles not eligible for inclusion, 60 articles not meeting primary endpoints, and 23 articles without specific data. Finally, nine articles were included in our models (three English articles and six Chinese articles). The identification and screening of studies are shown in the flow diagram (Figure 1).
3.2. Characteristics of the Included Studies. A total of nine RCTs published between 2009 and 2020 were included in this analysis. The studies reported data on a total of 924 patients with cancer, including 460 patients in the interventional group and 464 patients in the control group. The sample size of the included studies ranged from 60 to 127, and the intervention time ranged from 5 days to 8 weeks. Six studies assessed CRF endpoints with RPFS, four studies included an assessment of anxiety or depression using the Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS), and three studies included an assessment of the quality of life based on The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30 (EORTC-QLQ-C30) and Functional Assessment of Cancer Therapy General (FACT-G). The detailed characteristics are summarized in Table 1 [3, 4, 8–14].

3.3. Evaluation of the Methodological Quality of the Studies. Eight RCT studies used the randomization method. One study only mentioned randomization without illustrating the specific method. Three RCTs mentioned allocation concealment. Participants were blinded in two studies, and assessors were blinded in five studies. No statistically significant heterogeneity was observed among the nine studies (Figure 2).

3.4. Effects of TEAS on CRF. Six RCTs [3, 4, 10-13] that assessed the effect of TEAS on CRF (I² = 0%, P = 0.95) showed that the CRF of the intervention group was significantly lower than that of the control group (SWD = −0.83, 95% CI: −0.99 to −0.66, P < 0.05), as shown in Figure 3. The included studies were further analyzed according to whether the intervention duration exceeded 28 days. In cases where the duration of intervention was <28 days, the CRF in the intervention group was significantly lower than that of the control group (SWD = −0.88, 95% CI: −1.13 to −0.63, P < 0.05). Similarly, in studies with a duration of intervention ≥28 days, the CRF of the intervention group was also significantly lower than that of the control group (SWD = −0.79, 95% CI: −1.01 to −0.57, P < 0.05) (Figure 4). Subgroup analyses based on the sample size showed that statistical difference between the two groups can be observed regardless of whether the sample size was >100 (SWD = −0.92, 95% CI: −1.25 to −0.59, P < 0.05) or ≤100 (SWD = −0.80, 95% CI: −0.99 to −0.60, P < 0.05) (Figure 4).

3.5. Effects of TEAS on Negative Emotions. Four RCTs [8–10, 14] assessed the effect of TEAS on negative emotions in patients with cancer (I² = 93%, P < 0.05). The negative emotion in the intervention group was less severe than that in the control group (SWD = −1.46, 95% CI: −2.15 to −0.77, P < 0.05) (Figure 5). The analysis showed that there was a statistical difference between the two groups after intervention in terms of anxiety (SWD = −1.37, 95% CI: −2.34 to −0.40, P < 0.05) and depression (SWD = −1.64, 95% CI: −2.40 to −0.89, P < 0.05) (Figure 5).
3.6. Effects of TEAS on the Quality of Life. Three RCTs [11–13] assessed the impact of TEAS on the quality of life of patients with cancer ($I^2 = 83\%$, $P < 0.05$). The result showed that the quality of life in the intervention group was higher than that in the control group ($SWD = 0.74$, 95% CI: 0.20 to 1.27, $P < 0.05$) (Figure 6).

### Table 1: Characteristics of the included studies.

| Author, year | Sample size (n, T/C) | Age (years) (mean ± SD or range) | Gender (F/M) | Cancer type | Treatment method | Intervention time | Outcome indicator (scale) | Quality |
|--------------|----------------------|---------------------------------|--------------|-------------|-----------------|-------------------|--------------------------|---------|
| Tai et al., 2020 [8] | 127, 62/65 | - | - | Metastatic cancer | Surgery + chemotherapy | 5 days | Anxiety (SAS) | B |
| Gao and Luo, 2019 [9] | 84, 42/42 | T: 40–74; C: 41–75 | T: 19/23; C: 18/24 | Lung cancer | Chemotherapy | 8 days | Anxiety (SAS); depression (SDS); CRF (RPFS); anxiety (SAS); depression (SDS); CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Hu et al., 2019 [10] | 100, 50/50 | T: 65.24 ± 8.45; C: 64.70 ± 9.65 | T: 18/32; C: 18/32 | Lung cancer | Chemotherapy | 21 days | CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Huang and Zhao, 2019 [11] | 120, 60/60 | T: 58.25 ± 6.91; C: 59.13 ± 7.62 | T: 29/31; C: 32/28 | Uncertain | Surgery + chemotherapy | 8 weeks | CRF (RPFS); quality of life (FACT-G); CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Li et al., 2020 [12] | 108, 55/53 | T: 59.85 ± 10.34; C: 56.83 ± 11.06 | T: 28/27; C: 25/28 | Uncertain | Chemotherapy | 5 days | CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Wu et al., 2017 [13] | 113, 57/56 | T: 58.53 ± 8.42; C: 58.52 ± 10.65 | T: 15/42; C: 10/46 | Lung cancer | Chemotherapy | 28 days | CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Hou et al., 2017 [3] | 113, 57/56 | T: 58.06 ± 8.42; C: 58.27 ± 10.57 | T: 15/42; C: 10/46 | Lung cancer | Chemotherapy | 28 days | CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Sun, 2011 [4] | 60, 30/30 | T: 58.0 ± 6.1; C: 57.4 ± 6.9 | T: 16/14; C: 18/12 | Gastrointestinal cancer | Chemotherapy | 7 days | CRF (RPFS); quality of life (EORTc QLQ-C30) | B |
| Hu et al., 2017 [14] | 113, 51/62 | T: 59.98 ± 8.51; C: 58.81 ± 10.50 | T: 15/36; C: 11/51 | Lung cancer | Chemotherapy | 28 days | Anxiety (SAS) | A |

Undetermined in cancer type refers to the original literature indicating the inclusion of patients with unspecified tumor types. Full compliance with the risk of bias in the Cochrane RCTs is grade “A” (high-quality), and partial compliance with the original studies is grade “B” (moderate quality). T, interventional group; C, control group; F, female; M, male; CRF, cancer-related fatigue; RCT, randomized controlled trial; SAS, Self-rating Anxiety Scale; RPFS, Revised Piper Fatigue Scale; SD, standard deviation; SDS, Self-rating Depression Scale; EORTc QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.
| Study or Subgroup                      | Experimental Group | Control Group | Weight (%) | Std. Mean Difference | Std. Mean Difference |
|---------------------------------------|--------------------|---------------|------------|----------------------|---------------------|
|                                       | Mean (SD)          | Total (Mean)  | Total (SD) | IV.Random.95% CI     | IV.Random.95% CI    |
| 1.2.1 Intervention Time ≥28 days      | Hou et al 2017     | 2.08 (0.9)    | 57 (3)     | 1.29 (56)            | 18.4 (-0.84, -0.46) |
|                                       | Wu YF 2017         | 2 (3)         | 1.29 (56)  | 18.4 (-0.84, -0.46)  |                     |
|                                       | Huang F 2017       | 3             | 4.28 (60)  | 1.85 (20.1)          | -0.69 (-1.06, -0.32)|
| Subtotal (95% CI)                     | 172 (56.8)         |               |             | -0.79 (-1.01, -0.57) |                     |
|                                       |                    |               |            |                      |                     |
| Heterogeneity: Tau²=0.00; Chi²=0.42; df=2 (P = 0.81); I² = 0% | Test for overall effect; Z = 7.04 (P < 0.00001) |                     |
|                                       |                    |               |            |                      |                     |
| Test for subgroup differences; Chi²=0.30; df=1 (P = 0.58). I² = 0% | Favours (experimental) |                     |

**Figure 3:** Forest plot. Subgroup analysis of cancer-related fatigue in the interventional and control groups (intervention time). SD, standard deviation; CI, confidence interval.

| Study or Subgroup                      | Experimental Group | Control Group | Weight (%) | Std. Mean Difference | Std. Mean Difference |
|---------------------------------------|--------------------|---------------|------------|----------------------|---------------------|
|                                       | Mean (SD)          | Total (Mean)  | Total (SD) | IV.Random.95% CI     | IV.Random.95% CI    |
| 1.2.1 Intervention Time <28 days      | Sun QY 2011        | 6.06 (0.1)    | 30 (6.17)  | 0.11 (30)            | 9.3 (-1.03, -0.49)  |
|                                       | Li Y 2017          | 3.83 (0.66)   | 55 (4.44)  | 0.85 (53)            | 17.6 (-1.82, -0.43) |
|                                       | Hu MZ 2018         | 2.08 (0.89)   | 50 (3.02)  | 1.26 (50)            | 16.2 (-0.86, -0.44) |
| Subtotal (95% CI)                     | 135 (43.2)         |               |             | -0.88 (-1.13, -0.63) |                     |
|                                       |                    |               |            |                      |                     |
| Heterogeneity: Tau²=0.00; Chi²=0.40; df=2 (P = 0.82); I² = 0% | Test for overall effect; Z = 6.87 (P < 0.00001) |                     |
|                                       |                    |               |            |                      |                     |
| Total (95% CI)                        | 309 (100.0)        |               |             | -0.83 (-0.99, -0.66) |                     |
|                                       |                    |               |            |                      |                     |
| Heterogeneity: Tau²=0.00; Chi²=1.12; df=5 (P = 0.95); I² = 0% | Test for overall effect; Z = 9.82 (P < 0.00001) |                     |
|                                       |                    |               |            |                      |                     |
| Test for subgroup differences; Chi²=0.30; df=1 (P = 0.58). I² = 0% | Favours (experimental) |                     |

**Figure 4:** Forest plot. Subgroup analysis of cancer-related fatigue in the interventional and control groups (sample size). SD, standard deviation; CI, confidence interval.
3.7. Publication Bias. The funnel plots of CRF and negative emotion were not suggestive of publication bias as indicated by relative symmetry about the cumulative effect size (Figures 7 and 8).

4. Discussion

In this meta-analysis, we examined the effects of TEAS on the CRF, anxiety, depression, and quality of life in cancer patients and found that TEAS significantly improved the CRF, anxiety, depression, and quality of life in cancer patients.

We focused on the most common symptoms related to TEAS in nine studies with cancer patients, namely, CRF, anxiety, and depression. CRF is one of the most common symptoms of cancer survivors, and it is estimated that up to 90% and 27–82% of patients suffer from CRF during and after cancer treatment, respectively [15, 16]. CRF is defined as multidimensional and distressing fatigue related to cancer and/or cancer treatment that interferes with activities of daily living and significantly diminishes the quality of life [17]. Although chemotherapy and radiation therapy can be effective in treating physical disorders, they can hardly improve mental health. In fact, anxiety, stress, and depression often occur before and during cancer treatment [18]. As shown in our meta-analysis, TEAS can effectively reduce CRF; however, it must also be acknowledged that considerable heterogeneity exists between studies, including different tumor types, duration of intervention, and sample size. It has already been suggested that TEAS can reduce levels of inflammatory cytokines and improve CRF, which is a common and persistent adverse reaction of cancer treatment [3, 19].

Our results are consistent with the findings of several RCTs [8–10, 14], indicating that TEAS can significantly reduce anxiety and depressive symptoms in patients with
A variety of treatments can negatively affect cancer patients, leading to anxiety and depression symptoms [20]. Thoughtful application of TEAS can actually increase self-esteem and self-confidence, relieve discomfort, and alleviate anxiety and depression symptoms among cancer patients. In addition, our analysis showed that TEAS could significantly improve the quality of life of cancer patients. Nevertheless, our review found only three RCTs addressing the impact of TEAS on cancer patients. Taken together, the impact of TEAS on the quality of life of cancer patients is highly heterogeneous, partly due to different sample sizes, assessment scales, and others.

To the best of our knowledge, this is the first meta-analysis to investigate the effects of TEAS on CRF and negative emotions in patients with cancer. The quantitative evaluation of TEAS in our analysis can help strengthen the reliability of results and provide guidance for the clinical rehabilitation of cancer patients. Nevertheless, our study suffers from several limitations. First, our analysis was restricted to studies published in English or Chinese. Second, the review only analyzed a few studies with a small sample size.

5. Conclusions

In conclusion, TEAS can reduce CRF, anxiety, and depression and improve the quality of life of cancer patients. Given the above limitations, the current results should be interpreted with caution, and high-quality RCTs with larger sample sizes are warranted in the future to study the impact of TEAS on cancer patients.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

YH and FW conceptualized and designed the study. YH and FW provided administrative support. YH, MY, and CH were responsible for provision of study materials or patients. CH and DZ were responsible for collection and assembly of data. YH and DZ were involved in data analysis and interpretation. All authors wrote the manuscript. All authors approved the final manuscript.

References

[1] A. M. Tsimberidou, E. Fountzilas, M. Kurzrock, and R. Kurzrock, “Review of precision cancer medicine: Evolution of the treatment paradigm,” *Cancer Treat Review*, vol. 86, Article ID 102019, 2020.
[2] O. A. Agbejule, N. H. Hart, S. Ekberg et al., “Bridging the research to practice gap: a systematic scoping review of implementation of interventions for cancer-related fatigue management,” *BMCCancer*, vol. 21, no. 1, p. 809, 2021.
[3] L. Hou, C. Zhou, Y. Wu, and Y. Hu, “Transcutaneous electrical acupoint stimulation (TEAS) relieved cancer-related fatigue in non-small cell lung cancer (NSCLC) patients after chemotherapy,” *Journal of Thoracic Disease*, vol. 9, no. 7, pp. 1959–1966, 2017.
[4] Q. Z. Sun, “Effect of transcutaneous electrical acupoint stimulation used to alleviate cancer related fatigue in cancer chemotherapy patients,” *Chinese Journal of Modern Nursing*, vol. 17, pp. 3486–3488, 2011.
[5] D. H. Li, Y. Yao, and Q. Geng, “Chinese Society of Clinical Oncology guidelines for the diagnosis and treatment of lung cancer (2018),” *Journal of Clinical Surgery*, vol. 27, pp. 36–39, 2019.
[6] M. Cumpston, T. Li, M. J. Page et al., “Updated guidance for trusted systematic reviews: a new edition of the Cochrane
Handbook for Systematic Reviews of Interventions,” *Cochrane Database of Systematic Reviews*, vol. 10, Article ID ED000142, 2019.

[7] A. Ohlsson, “Systematic reviews - theory and practice,” *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 54, pp. 25–32, 1994.

[8] J. B. Tai, L. Hong, M. E. Ma, J. Xu, J. Q. Fang, and Y. Q. Jiang, “Evaluation of therapeutic effect of transcutaneous electrical acupoint stimulation on bone metastasis pain and its influence on immune function of patients,” *Annals of Palliative Medicine*, vol. 9, no. 5, pp. 2538–2544, 2020.

[9] L. Gao and J. Luo, “The effects of percutaneous electrical stimulation on bone marrow suppression and bad mood in patients with lung cancer undergoing chemotherapy,” *Chinese Medicine Modern Distance Education of China*, vol. 17, no. 7, pp. 72-73, 2019.

[10] M. Z. Hu, J. Zhao, and D. F. Gu, “Effect of percutaneous acupoint electrical stimulation combined with emotional release therapy on patients with lung cancer chemotherapy,” *Journal of Qilu Nursing*, vol. 25, no. 6, pp. 31–34, 2019.

[11] F. Huang and Y. Zhao, “A randomized controlled trial of percutaneous acupoint electrical stimulation in the treatment of cancer-induced fatigue,” *Chinese Journal of Rehabilitation Medicine*, vol. 34, pp. 688–692, 2019.

[12] Y. Li, H. B. Zhang, and Y. H. Liu, “Clinical effect of transcutaneous electric acupoint stimulation in the treatment of cancer-related fatigue after chemotherapy,” *China Medical Herald*, vol. 17, no. 12, pp. 149–152, 2020.

[13] Y. F. Wu, L. L. Hou, F. Gu, and Y. Yu, “Cancer-related fatigue in non-small cell lung cancer patients treated with transcutaneous electrical acupoint stimulation during periods of chemotherapy: an experimental pilot study,” *Chinese Journal of Practical Nursing*, vol. 33, pp. 693–698, 2017.

[14] Y. Q. Hu, Y. F. Wu, and L. L. Hou, “The effectiveness of electrical acupuncture stimulation in reducing levels of self-reported anxiety of lung cancer patients during palliative care: a pilot study,” *Iranian Journal of Public Health*, vol. 46, no. 8, pp. 1054–1061, 2017.

[15] M. Liao, Y. Xie, J. Yan et al., “Effect of acupuncture at 3 anti-fatigue acupoints in the treatment of cancer-related fatigue in patients with cancer,” *Medicine*, vol. 98, no. 23, Article ID e15919, 2019.

[16] D. Doege, M. S. Y. Thong, L. Weißer et al., “Health-related quality of life in very long-term cancer survivors 14-24 Years post-diagnosis compared to population controls: a population-based study,” *Cancers*, vol. 13, no. 11, p. 2754, 2021.

[17] Z. N. Huang, Q. Y. Chen, C. H. Zheng et al., “Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database,” *BMC Cancer*, vol. 18, no. 1, p. 1064, 2018.

[18] M. H. Antoni and F. S. Dhabhar, “The impact of psychosocial stress and stress management on immune responses in patients with cancer,” *Cancer*, vol. 125, no. 9, pp. 1417-1431, 2019.

[19] M. Yang, L. Liu, C. E. Gan et al., “Effects of home-based exercise on exercise capacity, symptoms, and quality of life in patients with lung cancer: a meta-analysis,” *European Journal of Oncology Nursing*, vol. 49, Article ID 101836, 2020.

[20] E. J. Morrison, P. J. Novotny, J. A. Sloan et al., “Emotional problems, quality of life, and symptom burden in patients with lung cancer,” *Clinical Lung Cancer*, vol. 18, no. 5, pp. 497–503, 2017.